FDA expands Revlimid indication

Share this content:

Celgene's Revlimid has a new indication. Reuters reports that the FDA has approved the cancer drug for newly diagnosed multiple myeloma patients.

The drug's official indication was previously limited to patients who had received at least one other medication.

Reuters says the first-line indication is unlikely to significantly boost sales because doctors have been prescribing Revlimid for this off-label use for some time.

Share this content:
Scroll down to see the next article